Wugen

fratricide-resistant CAR-T

oncology evolved

abstracts

Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of UCART and Long-Acting Interleukin-7 Combination Therapy
A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates UCART Proliferation, Differentiation, and Tumor Killing

wugen

Careers

Wugen is an Equal Opportunity Employer and does not discriminate against applicants due to race, ethnicity, gender, veteran status, or on the basis of disability or any other federal, state or local protected class.

PUBLICATIONS

An “off-the-shelf” fratricide-resistant CAR-T for the Treatment of T-cell hematologic malignancies

T-cell malignancies represent a group of hematologic cancers with high rates of relapse and mortality in patients for whom no effective targeted therapies exist. The shared expression of target antigens between chimeric antigen receptor (CAR) T-cells and malignant T-cells has limited the development.